BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 28867360)

  • 1. The use of TMZ embedded hydrogels for the treatment of orthotopic human glioma xenografts.
    Adhikari B; Li J; Brandel MG; Futalan D; Akers J; Deming T; Chen CC; Carter BS
    J Clin Neurosci; 2017 Nov; 45():288-292. PubMed ID: 28867360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy.
    Song S; Mao G; Du J; Zhu X
    Drug Deliv; 2016 May; 23(4):1404-8. PubMed ID: 26203687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma.
    Fourniols T; Randolph LD; Staub A; Vanvarenberg K; Leprince JG; Préat V; des Rieux A; Danhier F
    J Control Release; 2015 Jul; 210():95-104. PubMed ID: 25982679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
    Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
    Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
    Dong J; Zhou G; Tang D; Chen Y; Cui B; Dai X; Zhang J; Lan Q; Huang Q
    J Cancer Res Clin Oncol; 2012 Dec; 138(12):2079-84. PubMed ID: 22825126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro.
    Sun C; Yu Y; Wang L; Wu B; Xia L; Feng F; Ling Z; Wang S
    J Exp Clin Cancer Res; 2016 Feb; 35():32. PubMed ID: 26872471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Injectable Hydrogels for Localized Chemotherapy and Radiotherapy in Brain Tumors.
    Puente P; Fettig N; Luderer MJ; Jin A; Shah S; Muz B; Kapoor V; Goddu SM; Salama NN; Tsien C; Thotala D; Shoghi K; Rogers B; Azab AK
    J Pharm Sci; 2018 Mar; 107(3):922-933. PubMed ID: 29162424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide.
    López-Valero I; Saiz-Ladera C; Torres S; Hernández-Tiedra S; García-Taboada E; Rodríguez-Fornés F; Barba M; Dávila D; Salvador-Tormo N; Guzmán M; Sepúlveda JM; Sánchez-Gómez P; Lorente M; Velasco G
    Biochem Pharmacol; 2018 Nov; 157():266-274. PubMed ID: 30195736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effect of fibrin glue containing temozolomide against malignant glioma.
    Anai S; Hide T; Takezaki T; Kuroda J; Shinojima N; Makino K; Nakamura H; Yano S; Kuratsu J
    Cancer Sci; 2014 May; 105(5):583-91. PubMed ID: 24673719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence.
    Gilbert CA; Daou MC; Moser RP; Ross AH
    Cancer Res; 2010 Sep; 70(17):6870-9. PubMed ID: 20736377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic and therapeutic investigation of focused ultrasound-induced blood-brain barrier opening for enhanced temozolomide delivery in glioma treatment.
    Liu HL; Huang CY; Chen JY; Wang HY; Chen PY; Wei KC
    PLoS One; 2014; 9(12):e114311. PubMed ID: 25490097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
    Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
    J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
    Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
    Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.
    Huang TT; Hlavaty J; Ostertag D; Espinoza FL; Martin B; Petznek H; Rodriguez-Aguirre M; Ibañez CE; Kasahara N; Gunzburg W; Gruber HE; Pertschuk D; Jolly DJ; Robbins JM
    Cancer Gene Ther; 2013 Oct; 20(10):544-51. PubMed ID: 23969884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.
    Ferrer-Font L; Arias-Ramos N; Lope-Piedrafita S; Julià-Sapé M; Pumarola M; Arús C; Candiota AP
    NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28570014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
    Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide.
    Jaime-Ramirez AC; Dmitrieva N; Yoo JY; Banasavadi-Siddegowda Y; Zhang J; Relation T; Bolyard C; Wojton J; Kaur B
    J Gene Med; 2017 Mar; 19(3):. PubMed ID: 28087981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems.
    Toren A; Pismenyuk T; Yalon M; Freedman S; Simon AJ; Fisher T; Moshe I; Reichardt JK; Constantini S; Mardor Y; Last D; Guez D; Daniels D; Assoulin M; Mehrian-Shai R
    Oncotarget; 2016 Nov; 7(46):74860-74871. PubMed ID: 27556862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma.
    DI Cristofori A; Carrabba G; Lanfranchi G; Menghetti C; Rampini P; Caroli M
    Anticancer Res; 2013 Aug; 33(8):3383-9. PubMed ID: 23898108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.